This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MGEN vs. OPGN, CERS, CBIO, INZY, OMER, DRTS, CDXS, OABI, OSUR, and CRDFShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include OpGen (OPGN), Cerus (CERS), Crescent Biopharma (CBIO), Inozyme Pharma (INZY), Omeros (OMER), Alpha Tau Medical (DRTS), Codexis (CDXS), OmniAb (OABI), OraSure Technologies (OSUR), and Cardiff Oncology (CRDF). These companies are all part of the "medical" sector. Miragen Therapeutics vs. Its Competitors OpGen Cerus Crescent Biopharma Inozyme Pharma Omeros Alpha Tau Medical Codexis OmniAb OraSure Technologies Cardiff Oncology Miragen Therapeutics (NASDAQ:MGEN) and OpGen (NASDAQ:OPGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Does the media refer more to MGEN or OPGN? In the previous week, OpGen's average media sentiment score of 1.00 beat Miragen Therapeutics' score of 0.00 indicating that OpGen is being referred to more favorably in the news media. Company Overall Sentiment Miragen Therapeutics Neutral OpGen Positive Which has more volatility and risk, MGEN or OPGN? Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, OpGen has a beta of -1.66, meaning that its stock price is 266% less volatile than the S&P 500. Do insiders & institutionals have more ownership in MGEN or OPGN? 2.7% of OpGen shares are owned by institutional investors. 1.1% of Miragen Therapeutics shares are owned by company insiders. Comparatively, 43.8% of OpGen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, MGEN or OPGN? OpGen has lower revenue, but higher earnings than Miragen Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiragen Therapeutics$4.46M15.28-$41.87M-$20.09-0.87OpGen$2.67M0.15-$32.67MN/AN/A Is MGEN or OPGN more profitable? OpGen has a net margin of -1,140.36% compared to Miragen Therapeutics' net margin of -1,393.50%. OpGen's return on equity of 0.00% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Miragen Therapeutics-1,393.50% -141.66% -88.74% OpGen -1,140.36%N/A -287.58% SummaryOpGen beats Miragen Therapeutics on 6 of the 10 factors compared between the two stocks. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.16M$812K$5.59B$9.53BDividend YieldN/AN/A4.73%4.14%P/E Ratio-1.64N/A28.9123.88Price / Sales15.280.99445.5998.82Price / CashN/AN/A35.6858.35Price / Book2.570.118.165.60Net Income-$41.87M-$27.68M$3.25B$265.26M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$17.44+3.4%N/A+11.1%$68.16M$4.46M-1.6445High Trading VolumeOPGNOpGenN/A$0.04flatN/A-98.5%$396K$2.67M0.00100CERSCerus2.6207 of 5 stars$1.33-2.2%$3.50+163.2%-42.3%$259.98M$185.14M-13.30290News CoverageEarnings ReportCBIOCrescent Biopharma3.0196 of 5 stars$12.30-7.2%$25.67+108.7%N/A$259.03M$10K-0.2750Earnings ReportINZYInozyme Pharma2.126 of 5 stars$4.00flat$11.75+193.8%N/A$258.25MN/A-2.3750OMEROmeros3.7389 of 5 stars$3.97-4.3%$18.00+353.4%-7.6%$256.31MN/A-1.50210DRTSAlpha Tau Medical2.4026 of 5 stars$2.90-3.3%$8.00+175.9%+51.2%$254.46MN/A-6.3080News CoveragePositive NewsCDXSCodexis3.7805 of 5 stars$2.82-7.2%$11.00+290.1%-8.7%$251.85M$59.35M-2.85250News CoverageUpcoming EarningsOABIOmniAb2.8669 of 5 stars$1.96-4.9%$7.00+257.1%-51.5%$251.60M$26.74M-3.387OSUROraSure Technologies2.1428 of 5 stars$3.27-2.4%$3.00-8.3%-26.2%$250.58M$185.83M-7.79840Trending NewsCRDFCardiff Oncology1.8021 of 5 stars$3.31-11.3%$11.70+253.5%+24.5%$248.14M$680K-3.6020High Trading Volume Related Companies and Tools Related Companies OpGen Alternatives Cerus Alternatives Crescent Biopharma Alternatives Inozyme Pharma Alternatives Omeros Alternatives Alpha Tau Medical Alternatives Codexis Alternatives OmniAb Alternatives OraSure Technologies Alternatives Cardiff Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGEN) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGEN Stock Alerts